Ocular Drug Delivery: Present Innovations and Future Challenges
Ocular drug delivery has always been a challenge for ophthalmologists and drug-delivery scientists due to the presence of various anatomic and physiologic barriers. Inimitable static and dynamic ocular barriers not only exclude the entry of xenobiotics but also discourage the active absorption of th...
Gespeichert in:
| Veröffentlicht in: | The Journal of pharmacology and experimental therapeutics Jg. 370; H. 3; S. 602 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.09.2019
|
| Schlagworte: | |
| ISSN: | 1521-0103, 1521-0103 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Ocular drug delivery has always been a challenge for ophthalmologists and drug-delivery scientists due to the presence of various anatomic and physiologic barriers. Inimitable static and dynamic ocular barriers not only exclude the entry of xenobiotics but also discourage the active absorption of therapeutic agents. Designing an ideal delivery scheme should include enhanced drug bioavailability and controlled release of drug at the site of action, which can overcome various ocular barriers. Conventional ophthalmic medications include the use of topical eye drops and intravitreal injections of anti-vascular endothelial growth factor agent for treatment of anterior and posterior segment disorders, respectively. Current inventions for anterior ocular segment disorders such as punctum plugs, ocular implants, drug-eluting contact lenses, and ocular iontophoresis represent state-of-the-art inventions for sustained and controlled drug release. Parallel efforts for ocular drug delivery technologies for back of the eye disorders have resulted in the approval of various intravitreal implants. Novel drug-delivery technologies, including nanoparticles, nanomicelles, dendrimers, microneedles, liposomes, and nanowafers, are increasingly studied for anterior and posterior disorders. To achieve patient compliance for back of the eye disorders, novel approaches for noninvasive delivery of potent therapeutic agents are on the rise. In this review article, we discuss past successes, present inventions, and future challenges in ocular drug-delivery technologies. This expert opinion also discusses the future challenges for ocular drug-delivery systems and the clinical translatable potential of nanotechnology from benchtop to bedside. |
|---|---|
| AbstractList | Ocular drug delivery has always been a challenge for ophthalmologists and drug-delivery scientists due to the presence of various anatomic and physiologic barriers. Inimitable static and dynamic ocular barriers not only exclude the entry of xenobiotics but also discourage the active absorption of therapeutic agents. Designing an ideal delivery scheme should include enhanced drug bioavailability and controlled release of drug at the site of action, which can overcome various ocular barriers. Conventional ophthalmic medications include the use of topical eye drops and intravitreal injections of anti-vascular endothelial growth factor agent for treatment of anterior and posterior segment disorders, respectively. Current inventions for anterior ocular segment disorders such as punctum plugs, ocular implants, drug-eluting contact lenses, and ocular iontophoresis represent state-of-the-art inventions for sustained and controlled drug release. Parallel efforts for ocular drug delivery technologies for back of the eye disorders have resulted in the approval of various intravitreal implants. Novel drug-delivery technologies, including nanoparticles, nanomicelles, dendrimers, microneedles, liposomes, and nanowafers, are increasingly studied for anterior and posterior disorders. To achieve patient compliance for back of the eye disorders, novel approaches for noninvasive delivery of potent therapeutic agents are on the rise. In this review article, we discuss past successes, present inventions, and future challenges in ocular drug-delivery technologies. This expert opinion also discusses the future challenges for ocular drug-delivery systems and the clinical translatable potential of nanotechnology from benchtop to bedside.Ocular drug delivery has always been a challenge for ophthalmologists and drug-delivery scientists due to the presence of various anatomic and physiologic barriers. Inimitable static and dynamic ocular barriers not only exclude the entry of xenobiotics but also discourage the active absorption of therapeutic agents. Designing an ideal delivery scheme should include enhanced drug bioavailability and controlled release of drug at the site of action, which can overcome various ocular barriers. Conventional ophthalmic medications include the use of topical eye drops and intravitreal injections of anti-vascular endothelial growth factor agent for treatment of anterior and posterior segment disorders, respectively. Current inventions for anterior ocular segment disorders such as punctum plugs, ocular implants, drug-eluting contact lenses, and ocular iontophoresis represent state-of-the-art inventions for sustained and controlled drug release. Parallel efforts for ocular drug delivery technologies for back of the eye disorders have resulted in the approval of various intravitreal implants. Novel drug-delivery technologies, including nanoparticles, nanomicelles, dendrimers, microneedles, liposomes, and nanowafers, are increasingly studied for anterior and posterior disorders. To achieve patient compliance for back of the eye disorders, novel approaches for noninvasive delivery of potent therapeutic agents are on the rise. In this review article, we discuss past successes, present inventions, and future challenges in ocular drug-delivery technologies. This expert opinion also discusses the future challenges for ocular drug-delivery systems and the clinical translatable potential of nanotechnology from benchtop to bedside. Ocular drug delivery has always been a challenge for ophthalmologists and drug-delivery scientists due to the presence of various anatomic and physiologic barriers. Inimitable static and dynamic ocular barriers not only exclude the entry of xenobiotics but also discourage the active absorption of therapeutic agents. Designing an ideal delivery scheme should include enhanced drug bioavailability and controlled release of drug at the site of action, which can overcome various ocular barriers. Conventional ophthalmic medications include the use of topical eye drops and intravitreal injections of anti-vascular endothelial growth factor agent for treatment of anterior and posterior segment disorders, respectively. Current inventions for anterior ocular segment disorders such as punctum plugs, ocular implants, drug-eluting contact lenses, and ocular iontophoresis represent state-of-the-art inventions for sustained and controlled drug release. Parallel efforts for ocular drug delivery technologies for back of the eye disorders have resulted in the approval of various intravitreal implants. Novel drug-delivery technologies, including nanoparticles, nanomicelles, dendrimers, microneedles, liposomes, and nanowafers, are increasingly studied for anterior and posterior disorders. To achieve patient compliance for back of the eye disorders, novel approaches for noninvasive delivery of potent therapeutic agents are on the rise. In this review article, we discuss past successes, present inventions, and future challenges in ocular drug-delivery technologies. This expert opinion also discusses the future challenges for ocular drug-delivery systems and the clinical translatable potential of nanotechnology from benchtop to bedside. |
| Author | Gote, Vrinda Pal, Dhananjay Sicotte, Jeff Sikder, Sadia |
| Author_xml | – sequence: 1 givenname: Vrinda orcidid: 0000-0002-8967-601X surname: Gote fullname: Gote, Vrinda organization: Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri – sequence: 2 givenname: Sadia surname: Sikder fullname: Sikder, Sadia organization: Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri – sequence: 3 givenname: Jeff surname: Sicotte fullname: Sicotte, Jeff organization: Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri – sequence: 4 givenname: Dhananjay surname: Pal fullname: Pal, Dhananjay email: pald@umkc.edu organization: Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri pald@umkc.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31072813$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj89LwzAYhoNM3A89e5MevXTm-5J0rReRzelgMA96Lmn2dXZk6Uyawf57B07w9D6HhwfeIeu51hFjt8DHACgftnvqTlSMUWWFEBdsAAoh5cBF7x_32TCELecgZSauWF8An2AOYsCeViZa7ZOZj5tkRrY5kD8-Ju-eArkuWTjXHnTXtC4k2q2Teeyip2T6pa0lt6FwzS5rbQPdnHfEPucvH9O3dLl6XUyfl6kRed6lxHNRV1AgKA2ktKwzqYRBM9EGKxBZrbSeSAVFnSNlyE215sJIbSgjrAlH7P63u_ftd6TQlbsmGLJWO2pjKBEFFLzIuTipd2c1Vjtal3vf7LQ_ln-n8QddcVqi |
| CitedBy_id | crossref_primary_10_1016_j_preteyeres_2020_100862 crossref_primary_10_2174_0115748855287441240513081002 crossref_primary_10_1007_s40005_023_00653_8 crossref_primary_10_1007_s40883_025_00475_0 crossref_primary_10_3390_pharmaceutics14102052 crossref_primary_10_1002_pi_6450 crossref_primary_10_1002_pat_6079 crossref_primary_10_1016_j_ejpb_2023_02_011 crossref_primary_10_3389_fmed_2021_787644 crossref_primary_10_3390_pharmaceutics13091421 crossref_primary_10_3390_molecules29112609 crossref_primary_10_3390_pharmaceutics13050678 crossref_primary_10_2174_1574885518666230822144922 crossref_primary_10_3390_ma14154290 crossref_primary_10_1016_j_ejps_2023_106444 crossref_primary_10_1208_s12249_023_02673_x crossref_primary_10_3390_ijms242015352 crossref_primary_10_1016_j_jddst_2024_105886 crossref_primary_10_1016_j_exer_2025_110364 crossref_primary_10_1080_14760584_2022_2008246 crossref_primary_10_1080_09205063_2023_2187204 crossref_primary_10_1186_s12951_024_02448_x crossref_primary_10_1097_MS9_0000000000001399 crossref_primary_10_1155_2023_8827248 crossref_primary_10_2174_0115672018342369241018050810 crossref_primary_10_1016_j_ijpharm_2020_119688 crossref_primary_10_1038_s41598_025_91743_0 crossref_primary_10_1089_jop_2019_0105 crossref_primary_10_3389_fendo_2024_1347864 crossref_primary_10_1021_acsami_5c14464 crossref_primary_10_1089_jop_2022_0114 crossref_primary_10_1016_j_survophthal_2025_02_002 crossref_primary_10_1007_s12247_021_09537_6 crossref_primary_10_3390_pharmaceutics13091431 crossref_primary_10_1007_s13346_021_00966_x crossref_primary_10_3390_pharmaceutics14071479 crossref_primary_10_12991_jrespharm_1644619 crossref_primary_10_3390_pharmaceutics17050599 crossref_primary_10_3390_pharmaceutics12121177 crossref_primary_10_3390_pharmaceutics15041235 crossref_primary_10_1002_adhm_202501730 crossref_primary_10_1016_j_ijpharm_2021_120924 crossref_primary_10_4155_tde_2021_0039 crossref_primary_10_1002_smo_20230021 crossref_primary_10_3389_fchem_2021_694998 crossref_primary_10_3390_ijms23073541 crossref_primary_10_1097_ICO_0000000000003704 crossref_primary_10_1016_j_jconrel_2025_114078 crossref_primary_10_1080_17425247_2022_2135503 crossref_primary_10_1016_j_exer_2022_109300 crossref_primary_10_1016_j_ijpharm_2023_123439 crossref_primary_10_1007_s11095_024_03658_6 crossref_primary_10_1093_jpp_rgae129 crossref_primary_10_3390_pharmaceutics15010147 crossref_primary_10_1007_s10544_021_00567_y crossref_primary_10_1080_10717544_2023_2184312 crossref_primary_10_3390_pharmaceutics15020625 crossref_primary_10_1016_j_jddst_2023_104256 crossref_primary_10_1016_j_jconrel_2023_09_021 crossref_primary_10_3390_ph16111567 crossref_primary_10_1002_anbr_202200098 crossref_primary_10_1080_17435889_2025_2510197 crossref_primary_10_1016_j_molmed_2020_12_001 crossref_primary_10_3390_biomedicines9040396 crossref_primary_10_1080_00498254_2024_2341402 crossref_primary_10_1016_j_cej_2023_142889 crossref_primary_10_1016_j_heliyon_2023_e23810 crossref_primary_10_1016_j_ijpharm_2022_121627 crossref_primary_10_3389_fvets_2025_1574519 crossref_primary_10_1016_j_carbpol_2025_124139 crossref_primary_10_1007_s11095_024_03721_2 crossref_primary_10_1016_j_ejpb_2022_03_001 crossref_primary_10_1080_17425255_2020_1803278 crossref_primary_10_1080_17425247_2024_2431577 crossref_primary_10_3390_medicina58081031 crossref_primary_10_3390_ph13060126 crossref_primary_10_1016_j_ijpharm_2021_120591 crossref_primary_10_3390_molecules25194559 crossref_primary_10_1080_00914037_2024_2368895 crossref_primary_10_1016_j_jconrel_2022_08_040 crossref_primary_10_2147_IJN_S452134 crossref_primary_10_1007_s13346_021_01043_z crossref_primary_10_1016_j_addr_2024_115486 crossref_primary_10_1208_s12249_020_01774_1 crossref_primary_10_1016_j_exer_2025_110456 crossref_primary_10_1007_s10384_024_01070_6 crossref_primary_10_1016_j_ophtha_2020_10_022 crossref_primary_10_1016_j_ymeth_2024_12_008 crossref_primary_10_1016_j_ophtha_2020_10_023 crossref_primary_10_3762_bjnano_13_98 crossref_primary_10_1016_j_addr_2023_114904 crossref_primary_10_1038_s41578_021_00405_w crossref_primary_10_1002_advs_202409854 crossref_primary_10_1016_j_heliyon_2024_e26616 crossref_primary_10_1016_j_jconrel_2023_01_018 crossref_primary_10_2147_IJN_S375570 crossref_primary_10_3390_ma16103653 crossref_primary_10_3390_pharmaceutics14051019 crossref_primary_10_1080_09205063_2022_2088531 crossref_primary_10_1089_jop_2019_0135 crossref_primary_10_1089_jop_2024_0153 crossref_primary_10_1016_j_actbio_2024_07_003 crossref_primary_10_1016_j_ijbiomac_2025_140229 crossref_primary_10_1097_j_jcrs_0000000000000414 crossref_primary_10_1080_17425247_2022_2108397 crossref_primary_10_1007_s13346_024_01779_4 crossref_primary_10_1016_j_ijpharm_2019_118767 crossref_primary_10_3390_ijms23158529 crossref_primary_10_1038_s41598_021_03605_0 crossref_primary_10_1016_j_exer_2024_110165 crossref_primary_10_1002_adtp_202000160 crossref_primary_10_3389_fmolb_2022_931759 crossref_primary_10_1016_j_actbio_2023_12_021 crossref_primary_10_1080_09205063_2025_2561007 crossref_primary_10_1089_jop_2024_0024 crossref_primary_10_1016_j_ijpharm_2021_120332 crossref_primary_10_3390_pharmaceutics15092344 crossref_primary_10_1016_j_ejps_2023_106629 crossref_primary_10_1016_j_carbpol_2021_118006 crossref_primary_10_1016_j_ejpb_2022_05_013 crossref_primary_10_1016_j_matlet_2022_132174 crossref_primary_10_3390_pharmaceutics12060570 crossref_primary_10_3390_pharmaceutics14071431 crossref_primary_10_3390_pharmaceutics15041313 crossref_primary_10_3390_pharmaceutics13122050 crossref_primary_10_1016_j_actbio_2022_01_044 crossref_primary_10_3923_ijp_2021_15_27 crossref_primary_10_1016_j_ejpb_2022_09_023 crossref_primary_10_1002_advs_202207603 crossref_primary_10_1007_s12668_025_01895_6 crossref_primary_10_52711_0974_360X_2022_00628 crossref_primary_10_1016_j_actbio_2021_10_047 crossref_primary_10_1186_s43094_024_00587_4 crossref_primary_10_1007_s13346_024_01756_x crossref_primary_10_1016_j_jddst_2022_103327 crossref_primary_10_1016_j_cej_2025_159618 crossref_primary_10_1016_j_cis_2020_102121 crossref_primary_10_1038_s41568_020_00313_1 crossref_primary_10_1016_j_jddst_2024_105668 crossref_primary_10_1016_j_jddst_2021_103045 crossref_primary_10_1016_j_ijpharm_2021_121090 crossref_primary_10_1016_j_jconrel_2023_07_055 crossref_primary_10_3390_nano10071403 crossref_primary_10_1016_j_jconrel_2024_07_012 crossref_primary_10_1093_pnasnexus_pgaf250 crossref_primary_10_1016_j_ijbiomac_2021_02_057 crossref_primary_10_1208_s12249_025_03129_0 crossref_primary_10_3390_pharmaceutics12080702 crossref_primary_10_1021_acs_jmedchem_5c01459 crossref_primary_10_1016_j_ijpharm_2025_125959 crossref_primary_10_3390_ph14111201 crossref_primary_10_1080_17425247_2021_1872542 crossref_primary_10_1002_admt_202300171 crossref_primary_10_1016_j_ijbiomac_2023_126480 crossref_primary_10_1007_s12247_025_10091_8 crossref_primary_10_1016_j_jddst_2022_103333 crossref_primary_10_3390_life13020568 crossref_primary_10_1080_1061186X_2023_2271680 crossref_primary_10_1002_adfm_202407173 crossref_primary_10_2217_nnm_2023_0109 crossref_primary_10_2174_0113816128302570240627113909 crossref_primary_10_1016_j_cej_2021_129734 crossref_primary_10_1016_j_heliyon_2025_e42066 crossref_primary_10_3390_nano14080669 crossref_primary_10_1039_D4NR00611A crossref_primary_10_3390_pharmaceutics15071952 crossref_primary_10_1007_s42247_024_00643_y crossref_primary_10_3390_genes10090654 crossref_primary_10_1016_j_matlet_2022_133636 crossref_primary_10_3390_ph17101315 crossref_primary_10_3390_ph14090849 crossref_primary_10_1111_jdi_13740 crossref_primary_10_3390_pharmaceutics15061591 crossref_primary_10_1007_s10792_023_02637_x crossref_primary_10_3390_polym15010209 crossref_primary_10_1016_j_jconrel_2020_09_005 crossref_primary_10_1097_HM9_0000000000000020 crossref_primary_10_1002_adma_202302431 crossref_primary_10_1016_j_ejps_2022_106206 crossref_primary_10_3390_cells12071071 crossref_primary_10_1007_s12668_024_01447_4 crossref_primary_10_1007_s40123_023_00794_x crossref_primary_10_1016_j_clae_2025_102367 crossref_primary_10_1039_D5BM00325C crossref_primary_10_1016_j_heliyon_2025_e41881 crossref_primary_10_12968_opti_2021_6_8614 crossref_primary_10_1016_j_colsurfa_2023_131070 crossref_primary_10_1007_s40005_021_00554_8 crossref_primary_10_1080_20415990_2025_2552104 crossref_primary_10_7759_cureus_65368 crossref_primary_10_1016_j_jddst_2022_103872 crossref_primary_10_1007_s13346_022_01231_5 crossref_primary_10_1016_j_xphs_2024_09_001 crossref_primary_10_3390_pharmaceutics13060855 crossref_primary_10_1186_s12967_022_03738_4 crossref_primary_10_1002_adma_202407268 crossref_primary_10_1007_s11356_023_28904_z crossref_primary_10_1080_08820538_2021_1890793 crossref_primary_10_1080_10717544_2023_2219419 crossref_primary_10_1016_j_ijpharm_2023_122740 crossref_primary_10_1080_10717544_2021_1895911 crossref_primary_10_3390_cells10092394 crossref_primary_10_1002_advs_202004721 crossref_primary_10_1016_j_eurpolymj_2020_110024 crossref_primary_10_1002_gch2_202400181 crossref_primary_10_2174_1574885518666230626164030 crossref_primary_10_1016_j_clae_2021_101496 crossref_primary_10_1016_j_matlet_2024_137642 crossref_primary_10_3390_pharmaceutics12111072 crossref_primary_10_1080_17460441_2025_2556863 crossref_primary_10_1016_j_ijpharm_2021_120513 crossref_primary_10_1007_s12668_024_01631_6 crossref_primary_10_1016_j_omtn_2021_02_031 crossref_primary_10_1039_D0RA06681H crossref_primary_10_1016_j_ejpb_2025_114695 crossref_primary_10_1089_jop_2020_0078 crossref_primary_10_3390_bioengineering7030065 crossref_primary_10_3390_polym13183038 crossref_primary_10_1016_j_ejpb_2024_114276 crossref_primary_10_1208_s12249_024_02738_5 crossref_primary_10_3390_pharmaceutics15071959 crossref_primary_10_3390_cells14171405 crossref_primary_10_1080_17425247_2021_1846518 crossref_primary_10_1016_j_jconrel_2023_07_028 crossref_primary_10_1002_jcu_23214 crossref_primary_10_1016_j_jddst_2022_103654 crossref_primary_10_1016_j_jddst_2024_106448 crossref_primary_10_1186_s12951_023_01992_2 crossref_primary_10_1016_j_mtnano_2022_100218 crossref_primary_10_3389_fonc_2025_1661889 crossref_primary_10_1038_s41401_022_01005_2 crossref_primary_10_1016_j_ijpharm_2025_126058 crossref_primary_10_1152_physrev_00024_2023 crossref_primary_10_1016_j_addr_2023_114868 crossref_primary_10_1016_j_addr_2023_114869 crossref_primary_10_1097_j_jcrs_0000000000001225 crossref_primary_10_34133_jbioxresearch_0044 crossref_primary_10_4103_jpbs_JPBS_338_20 crossref_primary_10_1016_j_apmt_2025_102602 crossref_primary_10_1088_1361_6528_ad9df2 crossref_primary_10_1007_s44395_025_00009_1 crossref_primary_10_1016_j_jconrel_2022_03_031 crossref_primary_10_3390_cancers14010134 crossref_primary_10_1002_adma_202108389 crossref_primary_10_3390_biomedicines11051307 crossref_primary_10_3390_molecules26185577 crossref_primary_10_1016_j_clay_2023_107198 crossref_primary_10_1055_a_1665_3100 crossref_primary_10_1088_1361_6528_ac46d5 crossref_primary_10_70749_ijbr_v3i1_507 crossref_primary_10_3390_polym12071519 crossref_primary_10_1002_smll_202306222 crossref_primary_10_1167_iovs_64_7_39 crossref_primary_10_1177_25158414221112356 crossref_primary_10_2147_IJN_S417750 crossref_primary_10_1089_jop_2021_0111 crossref_primary_10_3389_fbioe_2021_791954 crossref_primary_10_1007_s13346_022_01196_5 crossref_primary_10_32604_jpm_2024_055821 crossref_primary_10_3390_ma17143454 crossref_primary_10_1016_j_addr_2022_114441 crossref_primary_10_1002_adhm_202304626 crossref_primary_10_3390_pharmaceutics16060697 crossref_primary_10_1016_j_ijpharm_2022_121772 crossref_primary_10_1016_j_ijpharm_2021_121012 crossref_primary_10_3390_ph16030474 crossref_primary_10_1016_j_jddst_2022_103721 crossref_primary_10_1002_advs_202403388 crossref_primary_10_3390_pharmaceutics15030734 crossref_primary_10_1016_j_ijpharm_2025_125793 crossref_primary_10_1016_j_actbio_2020_08_025 crossref_primary_10_1038_s41572_025_00646_x crossref_primary_10_1080_10837450_2021_1944206 crossref_primary_10_3390_gels11010019 crossref_primary_10_1186_s42269_023_01123_9 crossref_primary_10_1016_j_addr_2024_115321 crossref_primary_10_1016_j_biomaterials_2024_122853 crossref_primary_10_1007_s13534_024_00359_2 crossref_primary_10_2147_DDDT_S233047 crossref_primary_10_3390_pharmaceutics12121232 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics. |
| Copyright_xml | – notice: Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1124/jpet.119.256933 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1521-0103 |
| ExternalDocumentID | 31072813 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- -~X .55 .GJ 0R~ 18M 2WC 3O- 4.4 53G 5GY 5RE 5VS 8WZ A6W AALRI AAXUO AAYOK ABCQX ABIVO ABJNI ABOCM ABSQV ACGFO ACGFS ACNCT ADBBV ADCOW ADIYS AENEX AERNN AETEA AFFNX AFOSN AGFXO AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P F9R FDB GX1 H13 HZ~ INIJC KQ8 L7B LSO M41 MJL MVM NPM O9- OHT P2P R.V R0Z RHI ROL RPT TR2 UQL VH1 W8F WH7 WOQ X7M YBU YHG YQT ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c388t-e083fb19215a1e5a4f6453c2c7ac2b136f5aa74519f82e620cbd03c4ace6e2fe2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 323 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000485873600026&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1521-0103 |
| IngestDate | Thu Sep 04 17:42:17 EDT 2025 Sat Mar 08 01:25:25 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c388t-e083fb19215a1e5a4f6453c2c7ac2b136f5aa74519f82e620cbd03c4ace6e2fe2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-8967-601X |
| OpenAccessLink | https://jpet.aspetjournals.org/content/jpet/370/3/602.full.pdf |
| PMID | 31072813 |
| PQID | 2231909803 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2231909803 pubmed_primary_31072813 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-09-01 |
| PublicationDateYYYYMMDD | 2019-09-01 |
| PublicationDate_xml | – month: 09 year: 2019 text: 2019-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of pharmacology and experimental therapeutics |
| PublicationTitleAlternate | J Pharmacol Exp Ther |
| PublicationYear | 2019 |
| SSID | ssj0014463 |
| Score | 2.6875093 |
| SecondaryResourceType | review_article |
| Snippet | Ocular drug delivery has always been a challenge for ophthalmologists and drug-delivery scientists due to the presence of various anatomic and physiologic... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 602 |
| SubjectTerms | Administration, Ophthalmic Animals Drug Compounding Drug Delivery Systems - methods Eye - metabolism Humans Intravitreal Injections |
| Title | Ocular Drug Delivery: Present Innovations and Future Challenges |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31072813 https://www.proquest.com/docview/2231909803 |
| Volume | 370 |
| WOSCitedRecordID | wos000485873600026&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1dS8MwFA3qfPDF74_5RQTZ0-K6pGkaX4Y4h4LOPkzY20jSVBTp5roJ-_fetJ19EgRfSqEEwuUm5zT35hyELnXMJTeeJZ4JDPE1k0QDLSfGAlwbSLFE5zqzj6LfD4dDGZUHblnZVrncE_ONOh4bd0beAhgD7JKhxzqTT-Jco1x1tbTQWEU1BlTGZbUYVlUE-NXJG-wBoojzMyilfQDSWu_ASeFNXgHkS-ea-xu_zHGmt_XfGW6jzZJh4psiJXbQik13USMqJKoXTTyoblxlTdzAUSVevdhDnee8MRV3p_NX3LUfrm1jcY2j4pYSfvgxUc2wSmPcyyVJ8O3SkiXbRy-9u8HtPSlNFohhYTgjFjhYop0qGldty5WfBD5nhhqhDNVtFiRcKeFEaJKQ2oB6RsceM74yNrA0sfQAraXj1B4hLGSgqQxin0sF34XUvhKxMFY5UTbB6-hiGbgRJLGrTKjUjufZqApdHR0W0R9NCrWNEfBPQcM2O_7D6BO0AYSm7AE7RbUElrA9Q-vma_aWTc_z7IBnP3r6Bk43xNQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ocular+Drug+Delivery%3A+Present+Innovations+and+Future+Challenges&rft.jtitle=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.au=Gote%2C+Vrinda&rft.au=Sikder%2C+Sadia&rft.au=Sicotte%2C+Jeff&rft.au=Pal%2C+Dhananjay&rft.date=2019-09-01&rft.issn=1521-0103&rft.eissn=1521-0103&rft.volume=370&rft.issue=3&rft.spage=602&rft_id=info:doi/10.1124%2Fjpet.119.256933&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1521-0103&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1521-0103&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1521-0103&client=summon |